Generate Biomedicines Q2 FY26 net loss widens to $67.26 million; revenue drops to $6.31 million

• Generate Biomedicines posted a GAAP net loss of $67.26 million for the quarter ended June 30, 2026, widening from the prior-year quarter.
• Revenue fell 37.67% to $6.31 million, with collaboration revenue down as it nears completion of Novartis and Amgen obligations expected in 2027.
• Operating loss widened to $71.61 million as research and development expense rose 7.69% to $64.33 million, led by higher GB-0895 Phase 3 and CMC spending.
• General and administrative expense climbed 28.95% to $13.6 million, driven by higher stock-based compensation tied to options granted after the IPO.
• Cash, cash equivalents and marketable securities totaled $457.4 million at June 30, 2026; the company expects runway into the first half of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-336437), on August 06, 2026, and is solely responsible for the information contained therein.